P985 CONCOMITANT VERSUS SEQUENTIAL TREATMENT WITH TACE AND SORAFENIB IN HEPATOCELLULAR CARCINOMA PATIENTS

significantly associated with overall survival (OS) on univariate analysis and therefore included in multivariate analysis. Only Child– Pugh stage and HAP-Score were independent prognostic factors. The median OS for HAP A/B/C/D was 26/18/14/10 months (p < 0.0001). Conclusions: We could validate the HAP-score in an independent cohort of HCC patients treated with TACE. The HAP-score discriminates four different prognostic subgroups. Its clinical usefulness is limited by only 2 treatment options being available for this group of patients (TACE and drug treatment). A simplified score could be a useful tool for the selection of HCC patients for TACE.